Login to Your Account

Pharma Buyout Trend Continues

GSK Acquiring Young Antibody Firm Domantis For $454M Cash

By Jennifer Boggs

Monday, December 11, 2006
In the latest example of big pharma turning to biotech to beef up its research and development pipelines, GlaxoSmithKline plc agreed to acquire Domantis Ltd. for £230 million (US$454 million) in cash. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription